13.61
-0.87%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jiangxi Fushine Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300497.SZ. It has been listed since 22 December 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.18bn and a net loss of CN¥53.1m. At that date it held total assets of CN¥4.40bn and shareholders' equity of CN¥2.18bn.
Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of active pharmaceutical ingredient (API) and pharmaceutical intermediates. The company is headquartered in Jingdezhen, Jiangxi. The company went IPO on 2015-12-22. The firm's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The firm distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Dec 2015
- Employees
- 2,179
- Website
- fushine.cn ↗
Leadership
Pay as last reported
- Mr. Jianhua BaoChairman of the Board, President, since 2012CN¥1.3m
- Mr. Jizu ChengExecutive President, Director, since 2025
- Mr. Huiyue LiVice Chairman of the Board, since 2023
- Mr. Guang YangChief Financial Officer (Finance Director)
- Ms. Yun PengDeputy General Manager, Secretary of the Board
- Mr. Yinghui ChenDeputy General Manager
- Ms. Ying LiuDeputy General ManagerCN¥835,000
- Mr. Haipeng WeiDeputy General Manager
- Mr. Xiangming ZhangDeputy General ManagerCN¥735,000
- Mr. Zhenliang DaiStaff Elected Director, since 2016CN¥735,000
- Mr. Xiangqiang ChenIndependent Director
- Ms. Xiaoqing JiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jiangxi Fushine Pharmaceutical's sulbactam series enzyme inhibitor bulk drugs are key products in the EU market.
- The company's tazobactam series enzyme inhibitor bulk drugs are distributed to European Union markets.
- Jiangxi Fushine employs 2,179 full-time employees in the Health Care sector.
Weaknesses
- Jiangxi Fushine's API and pharmaceutical intermediates are limited to domestic and EU markets only.
- The company's product range focuses on enzyme inhibitor bulk drugs without diversification.
- Jiangxi Fushine's manufacturing capabilities are restricted to specific pharmaceutical intermediates.
Opportunities
- Expanding into Asian markets beyond the EU for pharmaceutical intermediates and API products.
- Increasing demand for carbapenems intermediates in global health care markets.
- Growing market for enzyme inhibitor bulk drugs in the European Union region.
Threats
- Competition from other Chinese pharmaceutical companies in the API market.
- Regulatory changes in the European Union affecting pharmaceutical imports.
- Dependence on EU market for tazobactam series product distribution.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.